Cargando…
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Autores principales: | Zhang, Qi, Riley-Gillis, Bridget, Han, Lina, Jia, Yannan, Lodi, Alessia, Zhang, Haijiao, Ganesan, Saravanan, Pan, Rongqing, Konoplev, Sergej N., Sweeney, Shannon R., Ryan, Jeremy A., Jitkova, Yulia, Dunner, Kenneth, Grosskurth, Shaun E., Vijay, Priyanka, Ghosh, Sujana, Lu, Charles, Ma, Wencai, Kurtz, Stephen, Ruvolo, Vivian R., Ma, Helen, Weng, Connie C., Ramage, Cassandra L., Baran, Natalia, Shi, Ce, Cai, Tianyu, Davis, Richard Eric, Battula, Venkata L., Mi, Yingchang, Wang, Jing, DiNardo, Courtney D., Andreeff, Michael, Tyner, Jeffery W., Schimmer, Aaron, Letai, Anthony, Padua, Rose Ann, Bueso-Ramos, Carlos E., Tiziani, Stefano, Leverson, Joel, Popovic, Relja, Konopleva, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975942/ https://www.ncbi.nlm.nih.gov/pubmed/35365596 http://dx.doi.org/10.1038/s41392-022-00958-4 |
Ejemplares similares
-
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022) -
Bone marrow stromal cells induce an ALDH(+) stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway
por: Yuan, Bin, et al.
Publicado: (2020) -
Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018) -
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021) -
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
por: Matre, Polina, et al.
Publicado: (2016)